Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD

Baruch D. Kuppermann, MD, PhD

Video
Published 2020

Related

Assessment of Progression of Geographic Atrophy in the FILLY Study
David R Lally, MD
On Demand Cases, Courses, and Papers
2020
Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Updates from the Field
2024
Episode 199: Nov/Dec 2019 Retinal Physician Preview: New Pathways for Dry AMD
Jayanth Sridhar, MD
Member Podcasts
2019

Category: AMD-Neovascular

See more